Widmer, A., K. Lillegard, K. Wood, M. Robles, R. Fan, F. Ye, J.R. Koethe, H.J. Silver, 2025. Consumption of tree nuts as snacks stimulates changes in plasma fatty acid profiles and adipose tissue gene expression in young adults at risk for metabolic syndrome. Clinical Nutrition. (48)25 – 34. https://doi.org/10.1016/j.clnu.2025.03.002.
Background and aims: The prevalence of metabolic syndrome has been increasing in young adults, concomitant with the occurrence of increased abdominal adiposity. We previously reported that consuming tree nuts, as replacement for typical high-carbohydrate snacks, reduces visceral fat and waist circumference in young adults who have one or more metabolic syndrome risk factors. We aimed to investigate the effects of tree nuts snack consumption on plasma and adipose tissue fatty acid profiles along with changes in the expression of adipose tissue genes involved in thermogenesis, glycemia, adipocyte signaling, lipolysis, and immunity. Methods: A randomized parallel-arm 16-week intervention trial was conducted in 84 adults aged 22-36 years. Participants in both groups were provided with caloric goals for weight maintenance, daily menus, and pre-portioned snacks at every other week visits with study registered dietitians. Changes in dietary fatty acid intakes, plasma and abdominal subcutaneous adipose tissue (SAT) triglycerides fatty acid profiles using gas-liquid chromatography, and the expression of 241 genes in abdominal SAT were evaluated. Results: Consuming tree nuts snacks increased mono- and polyunsaturated fatty acid intakes yielding a 9-fold greater dietary unsaturated to saturated fat ratio. The tree nuts snack group also had significantly greater improvements in plasma 16:1/16:0 ratio; plasma phospholipids oleic and gamma linolenic acid content; plasma diglycerides, triglycerides, and cholesterol esters oleic acid content; and total plasma monounsaturated fatty acids. While abdominal SAT only showed trends for increased oleic acid content and unsaturated to saturated fat ratio, the tree nuts snacks participants had altered expression of 13 genes in abdominal SAT that have roles in nutrient sensing, energy homeostasis, and vulnerability to obesity. Conclusions: Replacing typical high-carbohydrate snacks with tree nuts results in more favorable dietary, plasma, and adipose tissue fatty acid profiles that could aid in preventing the development of excess adiposity and cardiometabolic disease states including metabolic syndrome.
Hart, T.L., P.M. Kris-Etherton, K.S. Petersen, 2025. Consuming pecans as a snack improves lipids/lipoproteins and diet quality compared with usual diet in adults at increased risk of cardiometabolic diseases: a randomized controlled trial. Amer J Clin Nutr. ISSN 0002-9165,doi.org/10.1016/j.ajcnut.2025.01.024.
Background: The vascular and cardiometabolic effects of pecans are relatively understudied. Objectives: The aim was to examine how substitution of usual snack foods with 57g/d of pecans affects vascular health, risk factors for cardiometabolic diseases, and diet quality, compared with continuing usual intake in individuals at risk of cardiometabolic diseases. Methods: A 12-wk single-blinded, parallel, randomized controlled trial was conducted. Adults with ≥1 criterion for metabolic syndrome who were free from cardiovascular disease and type 2 diabetes were included. Participants were provided with 57g/d of pecans and instructed to replace the snacks usually consumed with the provided pecans. The control group was instructed to continue consuming their usual diet. Flow-mediated dilation (FMD),primary outcome, along with blood pressure, carotid-femoral pulse wave velocity (cf-PWV), lipids/lipoproteins, and glycemic control were measured at baseline and following the intervention. Participants completed 3 24-h recalls at 3 time points (baseline, week 6, and week 12) during the study (9 recalls in total). The Healthy Eating Index-2020 (HEI-2020) was calculated to assess diet quality. Results: In total, 138 participants (mean ± SD; 46 ± 13 y, 29.8 ± 3.7 kg/m2) were randomly assigned (69 per group). No between-group differences in FMD, cf-PWV, or blood pressure were observed. Compared with the usual diet group, pecan intake reduced total cholesterol (− 8.1 mg/dL; 95% confidence interval [CI]: −14.5, −1.7), LDL cholesterol ( −7.2 mg/dL; 95% CI −12.3, −2.1), non-HDL-cholesterol (− 9.5 mg/dL; 95% CI −15.3, −3.7), and triglycerides concentrations ( −16.4 mg/dL; 95% CI −30.0, −2.9). Weight tended to increase in the pecan group compared with the usual diet group (0.7 kg; 95% CI −0.1, 1.4). The HEI-2020 increased by 9.4 points (95% CI 5.0, 13.7) in the pecan group compared with the usual diet group. Conclusions: Replacing usual snacks with 57 g/d of pecans for 12-wk improves lipids/lipoproteins and diet quality but does not affect vascular health in adults at risk of cardiometabolic disease.
Meneguelli, T.S., A.C.P. Kravchychyn, A.L. Wendling, A.P. Dionísio, J. Bressan, H.S.D. Martino, E. Tako, H.H.M. Hermsdorff, 2024. Cashew nut (Anacardium occidentale L.) and cashew nut oil reduce cardiovascular risk factors in adults on weight-loss treatment: a randomized controlled three-arm trial (Brazilian Nuts Study). Front Nutr. 11:1407028. https://doi.org/10.3389/fnut.2024.1407028
Introduction: Cashew nut contains bioactive compounds that modulate satiety and food intake, but its effects on body fat during energy restriction remains unknown. This study aimed to assess the effects of cashew nut and cashew nut oil on body fat (primary outcome) as well as adiposity, cardiometabolic and liver function markers (secondary outcomes). Materials and methods: An eight-week (8-wk) randomized controlled-feeding study involved 68 adults with overweight/obesity (40 women, BMI: 33 ± 4 kg/m2). Participants were randomly assigned to one of the energy-restricted (−500 kcal/d) groups: control (CT, free-nuts), cashew nut (CN, 30 g/d), or cashew nut oil (OL, 30 mL/d). Body weight, body composition, and blood collection were assessed at the baseline and endpoint of the study. Results: After 8-wk, all groups reduced significantly body fat (CT: −3.1 ± 2.8 kg; CN: −3.3 ± 2.7 kg; OL: −1.8 ± 2.6 kg), body weight (CT: −4.2 ± 3.8 kg; CN: −3.9 ± 3.1 kg; OL: −3.4 ± 2.4 kg), waist (CT: −5.1 ± 4.6 cm; CN: −3.9 ± 3.9 cm; OL: −3.7 ± 5.3 cm) and hip circumferences (CT: −2.9 ± 3.0 cm; CN:−2.7 ± 3.1 cm; OL: −2.9 ± 2.3 cm). CN group reduced liver enzymes (AST: −3.1 ± 5.3 U/L; ALT:−6.0 ± 9.9 U/L), while the OL-group reduced LDL-c (−11.5 ± 21.8 mg/dL) and atherogenic index (−0.2 ± 0.5). Both intervention groups decreased neck circumference (CN: −1.0 ± 1.2 cm; OL: −0.5 ± 1.2 cm) and apo B (CN: −6.6 ± 10.7 mg/dL; OL: −7.0 ± 15.3 mg/dL). Conclusion: After an 8-wk energy-restricted intervention, all groups reduced body fat (kg), weight, and some others adiposity indicators, with no different effect of cashew nut or cashew nut oil. However, participants in the intervention groups experienced additional reductions in atherogenic marker, liver function biomarkers, and cardiovascular risk factors (neck circumference and apo B levels), with these effects observed across the OL group, CN group, and both intervention groups, respectively.
Nishi, S.K., I. Paz-Graniel, J. Ni, C. Valle-Hita, N. Khoury, J.F. Garcia-Gavilán, N. Babio, J. Salas-Salvadó, 2024. Effect of nut consumption on blood lipids: An updated systematic review and meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. https://doi.org/10.1016/j.numecd.2024.10.009
Aims: Nuts are nutrient-dense foods touted for their health-promoting effects, especially regarding cardiovascular health, yet inconsistencies in the literature remain in relation to their effect on blood lipids. Hence, a systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to determine the effect of nut intake on blood lipids. Data synthesis: MEDLINE-PubMed and Cochrane databases were searched. 113 unique trials met eligibility criteria (n = 8060 adults with various health status) assessing the effect of a median daily dose of 45.5 g/d of nuts compared to a non-nut control on blood lipid outcomes met inclusion criteria. Overall, nut consumption resulted in moderate reductions in total cholesterol (mean difference, −0.14 mmol/L [95 % confidence interval, −0.18 to −0.10 mmol/L]) and LDL-C (−0.12 mmol/L [-0.14 to −0.09 mmol/L]), with small reductions in triglycerides (−0.05 mmol/L [-0.07 to −0.03 mmol/L]), TC:HDL-C (−0.11 [-0.16 to −0.06]), LDL-C:HDL-C (−0.19 [-0.24 to −0.12]), and apolipoprotein B (−0.04 g/L [-0.06 to −0.02 g/L]). There was no significant impact on HDL-cholesterol or other assessed measures. Certainty of evidence was high for apolipoprotein A, and generally moderate/low for all other outcomes. Sensitivity analysis did not change the evidence on the main outcomes. Significant effect modifications in subgroup analysis were shown for most of the lipid parameters assessed. None of these subgroup effects altered the evidence of heterogeneity for any primary outcome. Conclusions: Current evidence provides a good indication that consuming nuts may advantageously affect blood lipids in adults with a mix of health status.
